Trials / Completed
CompletedNCT00215696
A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA™-GUIDED/MYOSTAR™ Catheter in "No Option" Patients With Class II-IV Stable Angina
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (planned)
- Sponsor
- GenVec · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to determine whether treatment with an experimental gene therapy (BIOBYPASS®) will reduce angina in study participants by stimulating the growth of new blood vessels. This will be measured by testing whether participants are able to exercise longer without experiencing angina after treatment, as compared to before treatment. Additionally, this study will collect information about any side effects that might be related to the treatment with the experimental therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | BioBypass® |
Timeline
- Start date
- 2005-04-01
- First posted
- 2005-09-22
- Last updated
- 2011-05-13
Locations
3 sites across 2 countries: Denmark, Israel
Source: ClinicalTrials.gov record NCT00215696. Inclusion in this directory is not an endorsement.